In this article, senior leaders at SFA Therapeutics emphasise the importance of re-establishing homeostasis in drug development approaches. The Promise…
Our pipeline includes treatments for Psoriasis, Liver Cancer (Hepatitis B, NASH and HCC), Ophthalmic Diseases, Cytokine Release Syndrome- a side effect in CAR-T, Prevention of Relapse/Recurrence in Leukemias, and other diseases.
Our microbiome-derived drugs are derived from natural substances and enable a new platform to develop treatments which have the potential to treat over 85 chronic inflammatory diseases currently afflicting patients, providing safer treatments than current therapies.
Liver Diseases: Hepatitis B, Steatosis, NASH, NAFLD
Dermatology: Bullous Pemphigus (Rare Autoimmune Disease)
Ophthalmology: Uveitis
Oncology: Liver Cancer, Hepatocellular Carcinoma (HCC), Prevention of Cytokine Storm in CAR T Therapy.
In this article, senior leaders at SFA Therapeutics emphasise the importance of re-establishing homeostasis in drug development approaches. The Promise…
JENKINTOWN, Pa., May 2, 2024 /PRNewswire/ — SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral small-molecule biosynthetic compounds for the treatment of inflammatory…
Ben Franklin Healthcare Investments Invests $1.3 Million in Four Companies Ben Franklin Healthcare Investments continues support of SFA Therapeutics with…
